Celgene's Narrow Beat on Second-Quarter Earnings Fails to Impress Investors; Shares Fall

Celgene Corporation (NASDAQ: CELG  ) reported second-quarter earnings before the bell today, posting an adjusted diluted EPS of $0.90 on a split-adjusted basis, narrowly beating the Street's expectations by $0.01. The company generated $1.873 billion in revenue during the quarter, topping consensus estimates by $23 million. 

The company's flagship cancer drug Revlimid generated worldwide sales of $1.214 billion for the quarter, an increase of 15% year-over-year. Based on these strong results, Celgene increased the upper bound of its 2014 sales guidance for Revlimid to $5.0 billion, from $4.95 billion. 

Abraxane sales also saw a nice uptick for the quarter, rising by 39% to $215 million, compared to the same period a year ago. This dramatic increase was due mainly to the drug's recent label expansion as a treatment for advanced pancreatic cancer. 

Pomalyst sales continued to show promise in the second quarter, increasing by 143% to $161 million, reflecting the company's substantial marketing efforts for the drug. 

Vidaza sales, by contrast, nosedived in the quarter by 28.1% to $152 million, compared to a year ago, as a result of generic azacitidine being introduced into the U.S. market.

Although Celgene posted a healthy 17% increase in revenue year-over-year for the quarter, shares are falling today following this earnings release. My view is that investors were expecting a wider beat based on the company's recent history of posting stellar quarterly results. 

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. Click here now.


Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3042431, ~/Articles/ArticleHandler.aspx, 9/2/2015 8:09:15 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

George Budwell

George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next generation vaccines, and cell therapies.

Today's Market

updated Moments ago Sponsored by:
DOW 16,351.38 293.03 1.82%
S&P 500 1,948.86 35.01 1.83%
NASD 4,749.98 113.87 2.46%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/2/2015 3:59 PM
CELG $119.58 Up +4.12 +3.57%
Celgene CAPS Rating: *****